Kryger Capital LLC Makes New Investment in Penumbra, Inc. $PEN

Kryger Capital LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN – Free Report) in the 1st quarter, Holdings Channel reports. The firm acquired 153,848 shares of the company’s stock, valued at approximately $50,519,000. Penumbra makes up 3.6% of Kryger Capital LLC’s holdings, making the stock its 12th biggest position.

Several other hedge funds and other institutional investors have also made changes to their positions in PEN. Larson Financial Group LLC grew its position in shares of Penumbra by 4,100.0% during the fourth quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after buying an additional 82 shares in the last quarter. CIBC Private Wealth Group LLC raised its holdings in Penumbra by 2,700.0% in the fourth quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Motiv8 Investments LLC purchased a new position in Penumbra in the fourth quarter worth approximately $27,000. Morse Asset Management Inc purchased a new position in Penumbra in the fourth quarter worth approximately $39,000. Finally, Farther Finance Advisors LLC grew its holdings in Penumbra by 27.1% during the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after acquiring an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Get Penumbra alerts:

Penumbra Trading Up 0.2%

NYSE PEN opened at $318.60 on Friday. The firm’s fifty day moving average price is $319.45 and its 200 day moving average price is $329.92. Penumbra, Inc. has a 12 month low of $221.26 and a 12 month high of $362.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The company has a market capitalization of $12.53 billion, a price-to-earnings ratio of 73.41, a price-to-earnings-growth ratio of 1.97 and a beta of 0.70.

Penumbra (NYSE:PEN – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company had revenue of $374.76 million during the quarter, compared to analysts’ expectations of $370.47 million. During the same period last year, the firm earned $0.83 earnings per share. Penumbra’s revenue was up 15.6% on a year-over-year basis. On average, sell-side analysts expect that Penumbra, Inc. will post 5.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

PEN has been the topic of a number of recent analyst reports. Zacks Research downgraded shares of Penumbra from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Citigroup decreased their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Evercore reissued an “outperform” rating and issued a $320.00 target price on shares of Penumbra in a report on Monday, July 6th. Finally, Wall Street Zen upgraded Penumbra to a “hold” rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Penumbra has a consensus rating of “Hold” and an average price target of $360.33.

Get Our Latest Stock Analysis on PEN

Penumbra Profile

(Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Further Reading

• Five stocks we like better than Penumbra
• AMD and Cerbras Create A New Blueprint For Hardware
• Intel Earnings Reveal Whether the Chip Selloff Created a Buy
• CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
• Plugging In: How Kinder Morgan Powers Up Profits

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.